TB-500 Titration in Hepatic Impairment: What Women Need to Know

What Is TB-500 and Why Does the Liver Matter?

TB-500 is a synthetic, shortened active fragment of thymosin beta-4 (Tβ4), an endogenous 43-amino-acid peptide expressed in virtually every nucleated human cell. The circulating concentration of thymosin beta-4 in healthy women ranges from approximately 2.2 to 3.4 micrograms per mL, with some research suggesting cycle-phase variation that has not been formally mapped. The peptide fragment TB-500 is compounded and sold in research contexts primarily for tissue repair, anti-inflammatory signaling, and, increasingly, off-label performance or recovery use.

The liver is central to peptide clearance. Small peptides below roughly 5 kDa are cleaved by serum and tissue peptidases, but hepatic uptake, first-pass extraction, and biliary excretion all contribute to the pharmacokinetic profile of thymosin-derived fragments. When hepatic function is impaired, two things can happen: clearance slows, raising peak and trough concentrations; and protein synthesis drops, changing the volume of distribution for any peptide that is albumin-associated.

Women are not a homogeneous group here. A 28-year-old woman with PCOS and nonalcoholic fatty liver disease (NAFLD) has a very different hepatic substrate from a 52-year-old woman in early post-menopause with estrogen-loss-related metabolic dysfunction liver disease, or a 38-year-old woman with autoimmune hepatitis. Each scenario calls for a different level of caution.

The Evidence Gap Women Deserve to Hear Plainly

There are no published randomized controlled trials of TB-500 or thymosin beta-4 fragment titration in humans with hepatic impairment. There are also no RCTs of this peptide in women of any hepatic status as a standalone pharmacokinetic study. What exists is:

• Preclinical rodent and in-vitro data on Tβ4's hepatoprotective signaling through the Akt/PI3K and Wnt pathway
• A small Phase II trial of full-length thymosin alpha-1 (not TB-500) in liver disease, which is a structurally distinct peptide
• Extrapolation from general small-peptide pharmacokinetics in Child-Pugh A, B, and C liver classification

This article does not manufacture precision that does not exist. Where data are extrapolated, that will be stated plainly.

How Hepatic Impairment Changes Peptide Pharmacokinetics

In women with any degree of liver disease, four pharmacokinetic variables shift in ways that directly affect TB-500 dosing.

1. Reduced Peptidase Activity and Prolonged Half-Life

The liver expresses dipeptidyl peptidase-4 (DPP-4), prolyl oligopeptidase, and other endo- and exopeptidases that participate in clearing circulating peptide fragments. DPP-4 activity is measurable reduced in Child-Pugh B and C cirrhosis, and while TB-500 is not a DPP-4 substrate in the classical sense, hepatic peptidase load contributes to its overall clearance. Reduced clearance means that the same dose produces a higher area-under-the-curve (AUC), effectively delivering more drug per injection.

2. Hypoalbuminemia and Altered Volume of Distribution

Women with cirrhosis or decompensated liver disease frequently have serum albumin below 3.5 g/dL. Peptides that bind albumin in transit have a larger free fraction when albumin is low. Albumin below 2.8 g/dL is one criterion for Child-Pugh C classification, the stage at which virtually all non-essential peptide use should halt. A larger free fraction may amplify both intended and unintended biological signaling.

3. Portosystemic Shunting

In portal hypertension, peptides that enter the portal system via subcutaneous absorption routes may bypass the liver entirely through shunt vasculature. The net effect on TB-500 exposure is unpredictable and has not been studied for this fragment specifically.

4. Coagulation Factor Depletion

Thymosin beta-4 fragments have shown some actin-sequestering and platelet-related activity in preclinical studies. Women with advanced liver disease already have coagulopathy from reduced synthesis of factors II, V, VII, IX, and X. Whether TB-500 meaningfully compounds bleeding risk at clinical doses is unknown, but the biological plausibility is sufficient to list this as a monitoring concern. Women on any anticoagulant therapy add a layer of additional unpredictability.

Child-Pugh Classification: Your Starting Framework

Because no TB-500-specific hepatic dosing table exists, the closest applicable framework is the Child-Pugh score used to classify liver disease severity and guide drug dosing for hepatically metabolized agents. This classification is validated in clinical pharmacology for dose adjustment decisions across many drug classes.

| Child-Pugh Class | Score | Bilirubin (mg/dL) | Albumin (g/dL) | INR | Encephalopathy | Ascites | Proposed TB-500 Approach | |---|---|---|---|---|---|---|---| | A (Mild) | 5-6 | <2 | >3.5 | <1.7 | None | None | Cautious titration; start 250 mcg twice weekly | | B (Moderate) | 7-9 | 2-3 | 2.8-3.5 | 1.7-2.3 | Minimal | Controlled | Avoid unless compelling reason; 125-250 mcg weekly at most | | C (Severe) | 10-15 | >3 | <2.8 | >2.3 | Moderate-severe | Refractory | Contraindicated; no use |

These proposed dose adjustments are constructed from general small-peptide PK principles and the Child-Pugh framework, not from direct TB-500 RCT data. They represent the conservative clinical reasoning this author and reviewer endorse given available preclinical information.

Titration Protocol for Women With Mild Hepatic Impairment (Child-Pugh A)

The following titration schedule is a clinically conservative proposal for a woman with Child-Pugh A hepatic impairment (confirmed by scored laboratory parameters) who has a documented reason for considering TB-500 under prescriber supervision. It is not validated in an RCT. No compounded TB-500 carries an FDA-approved label with hepatic dosing guidance.

Week 1-2: Test Dose Phase

Start at 250 mcg subcutaneously twice weekly (Monday and Thursday, for example). This is half the commonly cited healthy-adult starting dose of 500 mcg twice weekly. Use the smallest available insulin syringe to minimize injection-site variability. Inject into abdominal subcutaneous tissue for the most predictable absorption.

Obtain baseline labs before the first dose:

• Complete metabolic panel (CMP), including AST, ALT, alkaline phosphatase, total and direct bilirubin
• Serum albumin and total protein
• INR and PT
• CBC with differential

Week 3-4: First Assessment

Repeat CMP and LFTs at week 4. If AST or ALT has risen more than 3 times the upper limit of normal (ULN), stop TB-500 immediately and reassess with your prescribing clinician. If labs are stable and you have no new symptoms (nausea, right upper quadrant discomfort, jaundice, unusual bruising), you may continue at the same dose.

Week 5-8: Optional Uptitration

If the week 4 labs show no hepatotoxicity signal and symptoms are absent, the dose may be increased cautiously to 500 mcg twice weekly, which is the commonly cited standard adult starting dose. This is still conservative relative to some protocol-level doses of 1-2 mg twice weekly reported in wellness and performance contexts.

Do not proceed to uptitration if:

• Bilirubin has risen even modestly from baseline
• Albumin has fallen further
• INR has increased
• You are in the luteal phase of your cycle and experiencing unexplained fatigue or bloating (because these symptoms can overlap with both hepatic and hormonal fluctuation, making assessment unreliable)

Cycle-Phase Consideration for Premenopausal Women

Premenopausal women have not been studied in any TB-500 pharmacokinetic trial. Estrogen and progesterone both modulate hepatic enzyme expression. Estrogen induces CYP3A4 activity and alters glucuronidation, which may affect how rapidly peptide metabolites are cleared. This means your clearance capacity may differ between follicular and luteal phases. A practical implication: schedule your lab draws for the same cycle phase each time (early follicular, days 2-5, is easiest to standardize) to keep your LFT trend interpretable.

Titration Approach in Moderate Hepatic Impairment (Child-Pugh B)

Women with Child-Pugh B disease (score 7-9) should approach TB-500 with significant caution. The risk-benefit calculation changes substantially because:

• Albumin is already in the range where free-peptide fractions are unpredictable
• Coagulopathy is commonly present
• Encephalopathy risk means any CNS-active or metabolically active compound deserves extra scrutiny
• These women are often managing multiple medications for their liver disease, and peptide-drug interaction data do not exist

If a prescribing clinician still considers TB-500 appropriate after this calculus, the proposed maximum dose is 125-250 mcg once weekly, not twice weekly. LFTs should be checked every two weeks, not every four. Any worsening of Child-Pugh class is an immediate stop signal.

Severe Hepatic Impairment (Child-Pugh C): Do Not Use

Child-Pugh C is a hard stop for TB-500 use. Women in this category have refractory ascites, significant encephalopathy, INR above 2.3, and albumin below 2.8 g/dL. Adding any unvalidated peptide therapy in this population is not defensible. Period.

Women-Specific Conditions That Create Hepatic Risk

PCOS and NAFLD

Polycystic ovary syndrome affects 8 to 13 percent of women of reproductive age and carries a significantly elevated risk of nonalcoholic fatty liver disease (NAFLD), estimated at up to 30-40 percent of women with PCOS depending on BMI and insulin resistance severity. A young woman with PCOS who is exploring peptide therapy for inflammation or recovery may not realize her liver is already metabolically stressed. Baseline LFTs before starting TB-500 are non-negotiable in this group.

Perimenopausal and Postmenopausal Metabolic Liver Disease

Estrogen has hepatoprotective effects. The decline of estrogen at menopause is associated with increased NAFLD prevalence and severity, an effect confirmed in observational data comparing pre- and postmenopausal women. A perimenopausal woman, ages roughly 45-55, who does not have a previous liver diagnosis may still have subclinical steatosis or early fibrosis driven by estrogen withdrawal. Any peptide with uncertain hepatic clearance should be preceded by a liver function panel in this group.

Autoimmune Hepatitis

Autoimmune hepatitis disproportionately affects women, with a female-to-male ratio of approximately 4:1. Women on azathioprine, mycophenolate, or prednisone for autoimmune hepatitis face potential additive immunomodulatory effects from thymosin-related peptides, given Tβ4's role in T-cell modulation. This is an area of pure preclinical extrapolation, not clinical study, but the biological plausibility is real enough to require prescriber awareness.

Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) also skews heavily female. Over 90 percent of PBC patients are women, often diagnosed in their 40s and 50s. Women managing PBC with ursodeoxycholic acid or obeticholic acid have already impaired bile acid dynamics. Adding peptides with uncertain biliary excretion pathways creates a layer of pharmacokinetic unpredictability that cannot be resolved with current data.

Pregnancy, Lactation, and Contraception

TB-500 is contraindicated in pregnancy. This statement requires no equivocation. There are no human safety data, no animal reproductive toxicology studies published in peer-reviewed literature, and no mechanistic reassurance that a peptide involved in embryonic tissue remodeling and actin dynamics is safe during fetal development. Thymosin beta-4 itself plays documented roles in cardiac morphogenesis and epicardial development during embryogenesis. The active fragment TB-500 targets overlapping biological pathways. Using this peptide while pregnant, or while trying to conceive, is not supported by any available evidence.

Women of reproductive age must use reliable contraception while using TB-500. A barrier method alone is insufficient if pregnancy would pose significant risk. Combined hormonal contraception or an IUD is preferable.

Lactation: Transfer of TB-500 into human breast milk is entirely unknown. Endogenous thymosin beta-4 is present in human colostrum and milk at biologically active concentrations, as documented in proteomic studies of human milk. Whether exogenously administered synthetic fragment elevates milk concentrations or affects the nursing infant is unstudied. The precautionary position is to avoid TB-500 during breastfeeding.

Postpartum women with hepatic impairment carry an additional layer of complexity: postpartum hepatic dysfunction, including HELLP syndrome sequelae or postpartum autoimmune hepatitis flares, may transiently impair liver function for weeks to months after delivery. LFTs should be confirmed at a normal baseline, not simply assumed normal because the pregnancy has ended.

Monitoring Parameters: A Practical Checklist for Women

Every woman using TB-500 in the context of hepatic impairment (or suspected hepatic vulnerability) needs a structured monitoring plan. The following is a minimum standard, not a ceiling.

Before first dose:

• Child-Pugh score calculation (requires AST, ALT, bilirubin, albumin, INR, and clinical assessment of ascites and encephalopathy)
• Baseline weight and abdominal girth if ascites is a concern
• Medication reconciliation for any hepatically cleared drugs

Week 4:

• Repeat CMP with LFTs
• Symptom review: fatigue, right upper quadrant fullness, skin changes, urine color

Week 8:

• Repeat CMP with LFTs
• Reassess Child-Pugh class
• Decide whether to continue, adjust, or stop

Stop immediately if:

• AST or ALT rises more than 3x ULN from baseline, per FDA Drug-Induced Liver Injury Network (DILIN) stopping thresholds
• Bilirubin rises more than 2x baseline
• New jaundice, confusion, or asterixis appears
• INR increases by more than 0.5 from baseline

Who This May Be Right For, and Who It Is Not

Potentially Appropriate (With Strong Prescriber Oversight)

• Women with Child-Pugh A liver disease, stable labs, no coagulopathy, and a documented clinical rationale from their prescriber
• Women with PCOS-related mild NAFLD who have confirmed normal or near-normal LFTs after PCOS management optimization
• Perimenopausal women with physician-confirmed mild steatosis and no fibrosis on imaging, using hormone therapy that may itself reduce hepatic steatosis burden

Not Appropriate

• Any woman who is pregnant, trying to conceive, or breastfeeding
• Women with Child-Pugh B or C disease
• Women with autoimmune hepatitis who are on active immunosuppression
• Women with PBC and elevated bilirubin or alkaline phosphatase above 3x ULN
• Women with unexplained transaminase elevation that has not been evaluated
• Women taking hepatotoxic medications including methotrexate, isoniazid, valproate, or high-dose acetaminophen, because additive risk is unquantifiable with current data

The Research Gap: What Studies Are Needed

As WomanRx reviewer Dr. Maya Okafor, MD, stated during editorial review of this article: "The absence of sex-stratified pharmacokinetic data for TB-500 is not a minor gap, it is a structural failure of how peptide research has been conducted. Women with any degree of liver disease who are curious about this peptide deserve honest answers, and right now the honest answer is that we are working almost entirely from extrapolation. That has to change before this peptide moves into any standard-of-care conversation."

Studies that would materially change clinical guidance include:

• A Phase I PK trial of TB-500 in women across Child-Pugh A and B classes, with sex-stratified AUC and Cmax data
• Cycle-phase-controlled PK studies in premenopausal women
• Reproductive toxicology studies including embryo-fetal development endpoints
• Transfer studies in lactating women

Until these exist, all dosing recommendations, including those in this article, are educated frameworks, not evidence-based protocols.